Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penehyclidine for prevention of postoperative nausea and vomiting after laparoscopic sleeve gastrectomy
ChiCTR2300069082Phase 4Recruiting
- Sponsor
- Changzhou Second People's Hospital
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of penehyclidine in obesity and postoperative nausea and vomiting (PONV) (3 arms), sponsored by Changzhou Second People's Hospital. Primary endpoint: Severity of postoperative nausea and vomiting within 24 hours after surgery. Started Apr 2023; status: recruiting.
02
Drugs
penehyclidine
03
Conditions
obesitypostoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on ChiCTR2300069082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069082.